2810747-89-6
2810747-89-6
Chemical Structure
BLU2864
- CAS No.: 2810747-89-6
- Formula:C24H19F3N4O2
- Molecular Weight:452.43
IUPAC Name: N-((1R,2S)-5-(difluoromethyl)-7-fluoro-2-hydroxy-2,3-dihydro-1H-inden-1-yl)-6-(3-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)nicotinamide
InChIKey: VRPOVDLLZCQZEG-RXVVDRJESA-N
SMILES: FC1=CC(C(F)F)=CC2=C1[C@H]([C@@H](O)C2)NC(C(C=C3)=CN=C3C4=C(C(C)=CN5)C5=NC=C4)=O
Biological Activity: BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BLU2864 | 99.50% | BLU2864 is an orally active, highly selective, ATP-competitive PRKACA inhibitor (IC50=0.3 nM). BLU2864 shows anti-tumor activity. BLU2864 can be used in cancer and polycystic kidney disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Xiaofang Wang, et al. Protein Kinase A Downregulation Delays the Development and Progression of Polycystic Kidney Disease. J Am Soc Nephrol. 2022 Jun;33(6):1087-1104. [Content Brief]
- [2]. Stefanie S. Schalm, et al. Evaluation of PRKACA as a Therapeutic Target for Fibrolamellar Carcinoma. bioRxiv 2022.01.31.477690.
